Bart Heeg

1.5k citations

102 papers · 1.1k indexed · h-index 19

Impact in

Hematology top 2%
- Multiple Myeloma Research and Treatments
Psychiatry and Mental health top 5%
- Schizophrenia research and treatment

Papers in ⓘ

Hematology 38
- Multiple Myeloma Research and Treatments 26
- Chronic Myeloid Leukemia Treatments 9
Economics and Econometrics 26
- Health Systems, Economic Evaluations, Quality of Life 24

Co-authors: Ben A. van Hout (11 shared papers)Erik Buskens (6 shared papers)Mahmoud Hashim (18 shared papers)Maarten J. Postma (13 shared papers)Ben van Hout (7 shared papers)Annette Lam (17 shared papers)Meletios Α. Dimopoulos (13 shared papers)Margarita Kulakova (5 shared papers)
Journals: Value in Health (23 papers)Blood (13 papers)PharmacoEconomics (7 papers)Journal of Clinical Oncology (6 papers)Current Medical Research and Opinion (5 papers)
Partner nations: United States Germany Netherlands

In The Last Decade

Bart Heeg

90 papers receiving 1.0k citations

Peers

Countries citing papers authored by Bart Heeg

Since Specialization

Citations

This map shows the geographic impact of Bart Heeg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Heeg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Heeg more than expected).

Fields of papers citing papers by Bart Heeg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Heeg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Heeg. The network helps show where Bart Heeg may publish in the future.

Co-authors

The 25 scholars most cited alongside Bart Heeg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bart Heeg Line = papers co-authored together Bart Heeg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 102 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma Blood Advances ·Nikhil C. Munshi, Hervé Avet‐Loiseau, Kenneth C. Anderson, Paola Neri, Bruno Paiva, Mehmet Samur, Meletios Α. Dimopoulos, Margarita Kulakova, Annette Lam, Mahmoud Hashim, Jianming He, Bart Heeg, Jon Ukropec, Jessica Vermeulen, Sarah Côté, Nizar J. Bahlis	2020	226
2	Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany PharmacoEconomics ·Gerd Laux, Bart Heeg, Ben A. van Hout, Angelika Mehnert	2005	53
3	Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada PharmacoEconomics ·Pierre Chue, Bart Heeg, Erik Buskens, Ben A. van Hout	2005	44
4	Modelling the treated course of schizophrenia: Development of a discrete event simulation model PharmacoEconomics ·Bart Heeg, Erik Buskens, Martín Knapp, Gerda van Aalst, Pieter J. T. Dries, Lieuwe de Haan, Ben A. van Hout	2005	40
5	Modelling Approaches PharmacoEconomics ·Bart Heeg, Joep Damen, Erik Buskens, Sue Caleo, Frank de Charro, Ben A. van Hout	2008	40
6	Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections Current Medical Research and Opinion ·JFS Logman, Jennifer Stephens, Bart Heeg, Seema Haider, Joseph C. Cappelleri, Dilip Nathwani, Alan D. Tice, Ben A. van Hout	2010	38
7	MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes Clinical Lung Cancer ·Julien Mazières, H. Vioix, Boris M. Pfeiffer, Rhiannon I. Campden, Zhiyuan Chen, Bart Heeg, Alexis B. Cortot	2023	33
8	Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta‐regression Haemophilia ·M. Treur, Fiona B Mccracken, Bart Heeg, Ashish V. Joshi, Marc Botteman, Frank de Charro, BA Van Hout	2009	33
9	Proteasome inhibitors and IMiDs can overcome some high‐risk cytogenetics in multiple myeloma but not gain 1q21 European Journal Of Haematology ·Hareth Nahi, Thea Kristin Våtsveen, Johan Lund, Bart Heeg, Birgitte Preiss, Evren Alici, Michael Møller, Karin Fahl Wader, Hanne Elisabeth Højsgaard Møller, Lill Anny Gunnes Grøseth, Brian Østergaard, Hong Dai, Erik Holmberg, Gösta Gahrton, Anders Waage, Niels Abildgaard	2015	31
10	Which Factors Enhance Positive Drug Reimbursement Recommendation in Scotland? A Retrospective Analysis 2006–2013 Value in Health ·M. Charokopou, István Májer, Johan de Raad, Stefan Broekhuizen, Maarten J. Postma, Bart Heeg	2015	30
11	A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss BMC Health Services Research ·M. Treur, Bart Heeg, Hans‐Jürgen Möller, A Schmeding, Ben van Hout	2009	26
12	Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs Value in Health ·I. van Oostrum, Mario Ouwens, Antonio Remiro‐Azócar, Gianluca Baio, Maarten J. Postma, Erik Buskens, Bart Heeg	2021	23
13	Extrapolating Survival Data Using Historical Trial–Based a Priori Distributions Value in Health ·F Soikkeli, Mahmoud Hashim, Mario Ouwens, Maarten J. Postma, Bart Heeg	2019	22
14	The Cost-Effectiveness of Atypicals in the UK Value in Health ·Bart Heeg, Erik Buskens, Marc Botteman, Sue Caleo, Mike Ingham, Joep Damen, Frank de Charro, Ben van Hout	2008	22
15	Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention PharmacoEconomics ·Bart Heeg, Ron J.G. Peters, Marc Botteman, Ben A. van Hout	2007	21
16	Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non–Small Cell Lung Cancer Value in Health ·Mahmoud Hashim, Boris M. Pfeiffer, R. Bartsch, Maarten J. Postma, Bart Heeg	2017	21
17	Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies European Heart Journal - Quality of Care and Clinical Outcomes ·Mark H. Rozenbaum, Andrea García, Daniel Grima, Diana Tran, Rahul Bhambri, Michelle Stewart, Benjamin Li, Bart Heeg, Maarten J. Postma, Ahmad Masri	2021	21
18	Cost Effectiveness of Long-Acting Risperidone in Sweden Applied Health Economics and Health Policy ·Marja Hensen, Bart Heeg, Mickael Löthgren, Ben van Hout	2010	19
19	Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events PharmacoEconomics ·Bart Heeg, Joep Damen, Ben van Hout	2007	18
20	The cost-effectiveness of paliperidone extended release in Spain Journal of Medical Economics ·M. Treur, Enrique Baca, Julio Bobes, F. Cañas, Luis Salvador‐Carulla, Beatríz González, Bart Heeg	2012	16

About Bart Heeg

Bart Heeg is a scholar working on Hematology, Economics and Econometrics, Oncology, Statistics and Probability and Molecular Biology, having authored 102 papers that have together received 1.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (26 papers), Health Systems, Economic Evaluations, Quality of Life (24 papers), Statistical Methods in Clinical Trials (15 papers), Schizophrenia research and treatment (10 papers), Chronic Myeloid Leukemia Treatments (9 papers), Protein Degradation and Inhibitors (8 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Lung Cancer Treatments and Mutations (8 papers). The work is most often cited by research in Hematology (370 citations), Psychiatry and Mental health (192 citations), Economics and Econometrics (342 citations), Oncology (273 citations) and Statistics and Probability (59 citations). Bart Heeg has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Ben A. van Hout, Erik Buskens, Mahmoud Hashim, Maarten J. Postma, Ben van Hout, Annette Lam, Meletios Α. Dimopoulos, Margarita Kulakova, Jianming He and Frank de Charro. Their work appears in journals such as Value in Health, Blood, PharmacoEconomics, Journal of Clinical Oncology and Current Medical Research and Opinion.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact